StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Price Performance
Ayala Pharmaceuticals stock opened at $0.56 on Wednesday. Ayala Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.95. The company has a market capitalization of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. The firm’s fifty day moving average price is $0.69 and its 200 day moving average price is $0.74.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Stories
- Five stocks we like better than Ayala Pharmaceuticals
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Start Investing in Real Estate
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
